Weight Changes After Incretin-mimetics
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-50
SponsorMedical College of Wisconsin
About this trial
The goal of this study is to identify people at risk of weight regain after stopping an injectable weight loss drug. The main question the investigators aim to answer is: Can weight regain be predicted by measuring circulating Agouti-related peptide, a small protein coming from the brain?
Eligibility criteria
Qualifiers
adults 18 years or older
men and women
prescribed an incretin-mimetic for weight loss and for whom insurance coverage for this specific drug will lapse
any ethnicity
Disqualifiers
weight > or = 400 lb
type 1 or type 2 diabetes
patients taking steroid medications
anemia
Trial design
Treatments tested in this trial
- discontinuation of weight loss medication
Treatment groups
52 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Medical College of Wisconsin
Lead sponsor
University of Wisconsin, Milwaukee
Collaborator
Source ClinicalTrials.gov